Germany Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and Forecasts, 2026-2034

Last Updated: September 01, 2026 | Author: Dhanashri Chandgude | Format:

Germany Tulathromycin Market Size

The Germany tulathromycin market size was valued at USD 104 million in 2025 and is projected to grow from USD 114.19 million in 2026 to reach USD 241.24 million by 2034, growing at a CAGR of 9.8% during the forecast period 2026–2034.

Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin. The high prevalence of BRD and SRD drives the tulathromycin market. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin acts as an opportunity for the tulathromycin market.

Download a Free Sample To learn more about this report.

Animal Insights

Cattle dominates the market and is expected to register a CAGR of 6.6% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.

Germany Tulathromycin Market Size By Segments

Request Customizationto receive a tailored report.

Germany Tulathromycin Market Share By Segments

Speak to an Analystto discuss market opportunities.

Country Insights

The German tulathromycin market is expanding significantly and offers exciting potential. Tulathromycin, a veterinary antibiotic commonly used to treat bacterial and respiratory infections in animals, has become more popular in Germany due to several causes. The booming cattle business in Germany is one of the main factors driving the market. The nation is renowned for its robust agricultural industry, which includes raising cattle, swine, and poultry. Livestock farmers are putting more effort into keeping their animals healthy and productive as the demand for animal protein rises. Tulathromycin is essential in treating livestock respiratory disorders such as the bovine respiratory disease complex (BRD) and swine respiratory disease.

The well-developed German veterinary healthcare system comprises a network of veterinary clinics, hospitals, and experts. Producers of livestock and veterinarians are becoming more aware of the value of preventive healthcare practices and antibiotics when necessary. German veterinarians and livestock farmers favor tulathromycin since it is known to be an excellent antibiotic for the treatment and prevention of respiratory infections in animals.

List of Key and Emerging Players in Germany Tulathromycin Market

Zoetis

Zhejiang Genebest Pharmaceutical

Wisdom Pharmaceutical

Amicogen Biopharm

Hubei Honch Pharmaceutical

Livzon New North River Pharmaceutical

AVF Chemical Industrial

Jiangsu Lingyun Pharmaceutical

Key Industry Developments

March 2026

Zoetis continued expanding its livestock health portfolio across Europe, including Germany, through commercial support for Draxxin (tulathromycin) and other respiratory disease management products for cattle and swine.

January 2026

Elanco Animal Health continued commercialization of Increxxa (tulathromycin) across European Union markets, including Germany, supporting treatment of bovine and swine respiratory diseases.

October 2025

Boehringer Ingelheim expanded its cattle and swine health portfolio in Europe through continued investment in respiratory disease prevention and livestock health solutions, complementing antimicrobial treatment strategies.

Report Scope

Segmentation

By Animal Type 2

Cattle
Swine

Competitive Coverage Zoetis · Zhejiang Genebest Pharmaceutical · Wisdom Pharmaceutical · Amicogen Biopharm · Hubei Honch Pharmaceutical

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The market size is growing at a CAGR of 9.8% from 2026 to 2034.

high prevalence of BRD and SRD is the key driver for the growth of this market.

The key players in this market are The Zoetis, Zhejiang Genebest Pharmaceutical, Wisdom Pharmaceutical, Amicogen Biopharm, Hubei Honch Pharmaceutical Livzon New North River Pharmaceutical, AVF Chemical Industrial, Jiangsu Lingyun Pharmaceutical.

About the Author

Dhanashri Chandgude

Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.